Main Article Content
The Enzalutamide has low solubility and permeability which give rise to limited and variable bioavailability; its low stability makes it difficult to develop stable aqueous liquid formulations, the aim of this study was to investigate the effectiveness of a strategy based on the development of solid lipid Nanoparticles as an innovative formulation of enzalutamide with improved therapeutic efficacy. The Enzalutamide solid lipid nanoparticles were prepared by emulsification solvent evaporation technique by applying ultrasonic energy through Sonicator, the different formulations with various ratios of drug-lipid and surfactant were evaluated and optimised. The method used for the formulation of Enzalutamide containing soya lecithin solid lipid nanoparticles was solvent evaporation method followed by sonication to reduce the particle size. The prepared nanosuspensions were characterized for particle size, surface morphology by SEM, drug excipient compatibility by FTIR and in-vitro drug release studies. Formulation (F-8) showed the highest encapsulation efficiency. In this research, a drug encapsulation efficiency as high as 92.68 % has been achieved. It was found that as the concentration of soya lecithin increased, the encapsulation efficiency was also increased. The present study revealed that solvent evaporation technique followed by sonication can be used as an effective tool for preparation of Enzalutamide solid lipid nanoparticles.